|
Oltipraz in the Prevention of Lung Cancer in People Who Smoke Clinical Trials Info presented on Clinical Trials Search isn't intended to be a substitute for certified health advice, travels to or treatment by using a genuine physician. We are not physicians. Always consult your dr. on Oltipraz in the Prevention of Lung Cancer in People Who Smoke conditions. Clinical Trials Search.org is a site committed to listing clinical research studies in human subjects. Oltipraz in the Prevention of Lung Cancer in People Who Smoke Clinical research trials and Oltipraz in the Prevention of Lung Cancer in People Who Smoke health trials occur in hundreds of cities throughout the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectivity of new drugs. The propose of the studies / undertakings is to resolve certain human health questions. Clinical trials are a popular means for physicians, government agencies, and private sector companies to locate treatments for all sorts of conditions, including Oltipraz in the Prevention of Lung Cancer in People Who Smoke. Oltipraz in the Prevention of Lung Cancer in People Who Smoke Clinical Trials and other clinical trials permit volunteers to acquire medical treatment choices before they are available to the masses. Some times the test subjects obtain professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a Oltipraz in the Prevention of Lung Cancer in People Who Smoke clinical trial. Participants oftentimes recieve the most expert healthcare available for their Oltipraz in the Prevention of Lung Cancer in People Who Smoke condition. Hazards are a reality, however, and can include extra or frequent physician visits, health risks (potentially life-endangering), and/or the treatment being uneffective. Trials are federally governed with rigorous guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "O" Clinical Trials Conditions > Oltipraz in the Prevention of Lung Cancer in People Who Smoke  Oltipraz in the Prevention of Lung Cancer in People Who Smoke
Oltipraz in the Prevention of Lung Cancer in People Who Smoke
For Condition: prevention of lung cancer,Non-small cell lung cancer,Small Cell Lung Cancer
Status: No longer recruiting
Sponsor(s): National Cancer Institute (NCI) , Robert H. Lurie Cancer Center
Synopsis: RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development of cancer. PURPOSE: Randomized phase I trial to study the effectiveness of oltipraz in preventing lung cancer in people who smoke.
Details: OBJECTIVES: I. Determine the effect of oltipraz on the level of BP-7,8-diol-9,10-epoxide (BPDE) DNA adducts in the lung lining cells (macrophages and bronchial epithelial cells) of smokers. II. Determine the tolerability and toxicity of this treatment regimen in these patients. III. Determine the effect of this treatment regimen on the level of macromolecule adducts in the blood (e.g., BPDE DNA, BPDE hemoglobin, and 8-hydroxy-deoxyguanine), oral lining cells (BPDE DNA), bladder lining cells (4-aminobiphenyl DNA), and lung macrophages (8-hydroxy-deoxyguanine) in these patients. IV. Determine the effect of this treatment regimen on the change (decrease) in activation of NNK as measured by change (increase) in urinary NNAL plus NNAL glucuronide in these patients. V. Determine the effect of this treatment regimen on the oxidative state, glutathione-S-transferase activity, and superoxide dismutase 3 and phase II enzymes in the lungs and blood of these patients. VI. Compare the changes in oxidative state and phase II enzymes with changes in adduct levels in the lungs and blood of these patients. VII. Determine the correlation between oltipraz-induced changes in phase II enzymes and adduct formation with genotypic variation in glutathione-S-transferase isozymes in these patients. VIII. Compare the response to this treatment regimen in terms of oxidative state, phase II enzymes, and adduct formation in the lungs vs the blood in these patients. PROTOCOL OUTLINE: This is a randomized, double-blind, multicenter study. Patients are stratified according to participating center. Patients are randomized to one of three treatment arms. Arm I: Patients receive an oral placebo weekly. Arm II: Patients receive low-dose oral oltipraz weekly. Arm III: Patients receive high-dose oral oltipraz weekly. Treatment continues for 12 weeks in the absence of unacceptable toxicity. Patients are followed at 4 weeks. PROJECTED ACCRUAL: A total of 66 patients (22 per treatment arm) will be accrued for this study within 21 months.
Eligibility:
Study Type: Interventional, Prevention
Minimum Age/Maximum Age: 18 Years/
Genders:
Protocol Entry Criteria: PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- Current cigarette smokers - At least 20 cigarettes a day - No variation of more than 10 in the number of cigarettes smoked per day within the past 3 months - At least 10 years of smoking any amount - Failed to stop smoking after at least one attempt to quit within the last 3 years Prior stage I non-small cell lung cancer allowed if surgically resected with at least a lobectomy No concurrent evidence of lung cancer Willing to undergo 2 bronchoscopies --Prior/Concurrent Therapy-- Biologic therapy: Not specified Chemotherapy: At least 3 months since prior potential chemoprevention agent (e.g., oltipraz, retinoids, or acetylcysteine) Endocrine therapy: Not specified Radiotherapy: Not specified Surgery: See Disease Characteristics --Patient Characteristics-- Age: 18 and over Performance status: ECOG 0 Life expectancy: Not specified Hematopoietic: - CBC normal - Hemostasis normal Hepatic: PT and PTT normal Renal: - Blood chemistries normal - Nonfasting glucose no greater than 200 mg/dL - No active renal disease - No urinary tract infection by urinalysis (trace protein allowed) Cardiovascular: - EKG normal - No coronary artery disease requiring continuous medication Pulmonary: - Chest radiograph normal (postsurgical changes allowed) - No acute or significant chronic abnormality - FEV1 greater than 1.8 L or 75% predicted - No chronic obstructive pulmonary disease requiring continuous medication Other: - No known hypersensitivity or prior adverse reaction to oltipraz - No inmates or prisoners - No medical or psychological condition that would preclude study (e.g., acute psychosis) - No prior malignancy except nonmelanomatous skin cancer, cervical dysplasia, or curatively treated stage I or II cancer of the head and neck - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception during and for 6 months after study
Total Enrollment:
Location and Contact Information:
Overall Study Official:
RaymondBergan, Study Chair, Robert H. Lurie Cancer Center
Duke Comprehensive Cancer Center
Durham, North Carolina, 27710
United States
Robert H. Lurie Comprehensive Cancer Center, Northwestern University
Chicago, Illinois, 60611-3013
United States
Additional Information:
Study ID Numbers: CDR0000068190; NCI-P00-0167,NU-00L1,DUMC-000346-00-2
Study Start Date: August 2000
Record last reviewed: May 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00006457
Other Prevention Of Lung Cancer Studies:
1. Phase III Randomized Study of Nicotine Inhaler Versus Bupropion Versus Nicotine Inhaler Plus Bupropion for Smoking Cessation and Prevention of Relapse in Participants Who Currently Smoke
2. Oltipraz in the Prevention of Lung Cancer in People Who Smoke
Related Studies:
Other prevention of lung cancer Clinical Trials
Other North Carolina Clinical Trials
Other Durham Clinical Trials
Oltipraz in the Prevention of Lung Cancer in People Who Smoke
|
|
|
|
|
|
|
|
